Several other equities research analysts also recently issued reports on ANNX. HC Wainwright reiterated a "buy" rating and issued a $30.00 target price on shares of Annexon in a research note on Friday. Needham & Company LLC reaffirmed a "buy" rating and issued a $16.00 price objective on shares of Annexon in a research report on Friday. Six investment analysts have rated the stock with a buy rating, According to MarketBeat, the company presently has an average rating of "Buy" and an average target price of $15.80.
View Our Latest Stock Analysis on Annexon
Shares of NASDAQ:ANNX traded down $0.12 during midday trading on Friday, hitting $6.21. The stock had a trading volume of 78,210 shares, compared to its average volume of 1,810,987. The company has a market cap of $656.09 million, a P/E ratio of -5.05 and a beta of 1.23. Annexon has a 12 month low of $2.27 and a 12 month high of $8.40. The business's 50-day simple moving average is $6.89 and its 200-day simple moving average is $5.90.
Annexon (NASDAQ:ANNX - Get Free Report) last announced its quarterly earnings data on Monday, August 12th. The company reported ($0.23) EPS for the quarter, meeting analysts' consensus estimates of ($0.23). As a group, equities analysts predict that Annexon will post -0.97 earnings per share for the current year.
In related news, EVP Ted Yednock sold 5,500 shares of the firm's stock in a transaction dated Thursday, September 5th. The shares were sold at an average price of $5.64, for a total transaction of $31,020.00. Following the transaction, the executive vice president now directly owns 10,000 shares of the company's stock, valued at approximately $56,400. This trade represents a 35.48 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Over the last quarter, insiders have sold 20,908 shares of company stock worth $135,768. Company insiders own 12.67% of the company's stock.
A number of institutional investors have recently bought and sold shares of the business. Ameritas Investment Partners Inc. boosted its stake in shares of Annexon by 78.2% in the first quarter. Ameritas Investment Partners Inc. now owns 6,718 shares of the company's stock valued at $48,000 after buying an additional 2,949 shares during the period. Sandia Investment Management LP bought a new stake in shares of Annexon during the 2nd quarter valued at $49,000. Victory Capital Management Inc. acquired a new stake in shares of Annexon during the 2nd quarter worth $51,000. Principal Financial Group Inc. bought a new position in shares of Annexon in the second quarter worth $56,000. Finally, Comerica Bank acquired a new position in Annexon in the first quarter valued at about $72,000.
Annexon, Inc, a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. Its lead candidate is ANX005, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase II clinical trial for the treatment of amyotrophic lateral sclerosis.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
Before you consider Annexon, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Annexon wasn't on the list.
While Annexon currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.